Branka Zorc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Branka Zorc has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Kristina Pavić
Department of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
10 shared publications - Zrinka Rajić
Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, 10000 Zagreb, Croatia
10 shared publications Ivana Perković
Department of Medicinal Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
9 shared publications- Diana Fontinha
GIMM - Gulbenkian Institute for Molecular Medicine, Avenida Prof. Egas Moniz, 1649-039 Lisboa, Portugal
7 shared publications - Marijeta Kralj
Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia
7 shared publications - Miguel Prudêncio
GIMM - Gulbenkian Institute for Molecular Medicine, Avenida Prof. Egas Moniz, Lisboa, Portugal
7 shared publications
Latest Publications
- 8 January 2022
- Published by Springer Nature in Molecular Diversity
- Vol. 26 (5) , 2595-2612
Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity
In the present study, we report the design and synthesis of novel amide-type hybrid molecules based on anthranilic acid and quinoline or β-carboline heterocyclic scaffolds. Three types of biological screenings were performed: (i) in vitro antiproliferative screening against a panel of solid tumor and leukemia cell lines, (ii) antiviral screening against several RNA viruses, and (iii) anti-quorum sensing screening using gram-negative Chromobacterium violaceum as the reporter strain. Antiproliferative screening revealed a high activity of several compounds. Anthranilamides 12 and 13 with chloroquine core and halogenated anthranilic acid were the most active agents toward diverse cancer cell lines such as glioblastoma, pancreatic adenocarcinoma, colorectal carcinoma, lung carcinoma, acute lymphoblastic, acute myeloid, chronic myeloid leukemia, and non-Hodgkin lymphoma, but also against noncancerous cell lines. Boc-protected analogs 2 and 3 showed moderate activities against the tested cancer cells without toxic effects against noncancerous cells. A nonhalogenated quinoline derivative 10 with N-benzylanthranilic acid residue was equally active as 12 and 13 and selective toward tumor cells. Chloroquine and quinoline anthranilamides 10–13 exerted pronounced antiviral effect against human coronaviruses 229E and OC43, whereas 12 and 13 against coronavirus OC43 (EC50 values in low micromolar range; selectivity indices from 4.6 to > 10.4). Anthranilamides 14 and 16 with PQ core inhibited HIV-1 with EC50 values of 9.3 and 14.1 µM, respectively. Compound 13 displayed significant anti-quorum/biofilm effect against the quorum sensing reporter strain (IC50 of 3.7 μM) with no apparent bactericidal effect. Graphical abstract
- 8 January 2022
- Published by Springer Nature in Molecular Diversity
- Vol. 26 (5) , 2595-2612
Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity
In the present study, we report the design and synthesis of novel amide-type hybrid molecules based on anthranilic acid and quinoline or β-carboline heterocyclic scaffolds. Three types of biological screenings were performed: (i) in vitro antiproliferative screening against a panel of solid tumor and leukemia cell lines, (ii) antiviral screening against several RNA viruses, and (iii) anti-quorum sensing screening using gram-negative Chromobacterium violaceum as the reporter strain. Antiproliferative screening revealed a high activity of several compounds. Anthranilamides 12 and 13 with chloroquine core and halogenated anthranilic acid were the most active agents toward diverse cancer cell lines such as glioblastoma, pancreatic adenocarcinoma, colorectal carcinoma, lung carcinoma, acute lymphoblastic, acute myeloid, chronic myeloid leukemia, and non-Hodgkin lymphoma, but also against noncancerous cell lines. Boc-protected analogs 2 and 3 showed moderate activities against the tested cancer cells without toxic effects against noncancerous cells. A nonhalogenated quinoline derivative 10 with N-benzylanthranilic acid residue was equally active as 12 and 13 and selective toward tumor cells. Chloroquine and quinoline anthranilamides 10–13 exerted pronounced antiviral effect against human coronaviruses 229E and OC43, whereas 12 and 13 against coronavirus OC43 (EC50 values in low micromolar range; selectivity indices from 4.6 to > 10.4). Anthranilamides 14 and 16 with PQ core inhibited HIV-1 with EC50 values of 9.3 and 14.1 µM, respectively. Compound 13 displayed significant anti-quorum/biofilm effect against the quorum sensing reporter strain (IC50 of 3.7 μM) with no apparent bactericidal effect. Graphical abstract
- Open Access
- 11 October 2020
- Published by Springer Nature in Molecular Diversity
- Vol. 26 (1) , 1-14
Itaconic acid hybrids as potential anticancer agents
In this paper, we report the synthesis of novel hybrids 2–14 based on itaconic acid and fluoroaniline, pyridine, indole and quinoline scaffolds. Itaconic acid is a naturally occurring compound with a Michael acceptor moiety, a key structural feature in several anticancer and antiviral drugs, responsible for the covalent binding of a drug to the cysteine residue of a specific protein. Aromatic parts of the hybrids also come from the substances reported as anticancer or antiviral agents. The synthetic route employed to access the amido-ester hybrids 2–13 used monomethyl itaconate or monomethyl itaconyl chloride and corresponding amines as the starting materials. Dimers 14 and 15 with two aminoindole or mefloquine moieties were prepared from itaconic acid and corresponding amino derivative, using standard coupling conditions (HATU/DIEA). All hybrids exerted anticancer effects in vitro against almost all the tumour cell lines that were evaluated (MCF-7, HCT 116, H460, LN-229, Capan-1, DND-41, HL-60, K-562, Z-138). Solid tumour cells were, in general, more responsive than the haematological cancer cells. The MCF-7 breast adenocarcinoma cell line appeared the most sensitive. Amido-ester 12 with chloroquine core and mefloquine homodimer 15 showed the highest activity with GI50 values between 0.7 and 8.6 µM. In addition, compound 15 also exerted antiviral activity against Zika virus and Coxsackievirus B4 in low micromolar concentrations. Graphic abstract
- 11 October 2020
- Published by Springer Nature in Molecular Diversity
- Vol. 26 (1) , 1-14
Open AccessItaconic acid hybrids as potential anticancer agents
In this paper, we report the synthesis of novel hybrids 2–14 based on itaconic acid and fluoroaniline, pyridine, indole and quinoline scaffolds. Itaconic acid is a naturally occurring compound with a Michael acceptor moiety, a key structural feature in several anticancer and antiviral drugs, responsible for the covalent binding of a drug to the cysteine residue of a specific protein. Aromatic parts of the hybrids also come from the substances reported as anticancer or antiviral agents. The synthetic route employed to access the amido-ester hybrids 2–13 used monomethyl itaconate or monomethyl itaconyl chloride and corresponding amines as the starting materials. Dimers 14 and 15 with two aminoindole or mefloquine moieties were prepared from itaconic acid and corresponding amino derivative, using standard coupling conditions (HATU/DIEA). All hybrids exerted anticancer effects in vitro against almost all the tumour cell lines that were evaluated (MCF-7, HCT 116, H460, LN-229, Capan-1, DND-41, HL-60, K-562, Z-138). Solid tumour cells were, in general, more responsive than the haematological cancer cells. The MCF-7 breast adenocarcinoma cell line appeared the most sensitive. Amido-ester 12 with chloroquine core and mefloquine homodimer 15 showed the highest activity with GI50 values between 0.7 and 8.6 µM. In addition, compound 15 also exerted antiviral activity against Zika virus and Coxsackievirus B4 in low micromolar concentrations. Graphic abstract
- Open Access
Novel Harmicines with Improved Potency against Plasmodium
Harmicines represent hybrid compounds composed of β-carboline alkaloid harmine and cinnamic acid derivatives (CADs). In this paper we report the synthesis of amide-type harmicines and the evaluation of their biological activity. N-harmicines 5a–f and O-harmicines 6a–h were prepared by a straightforward synthetic procedure, from harmine-based amines and CADs using standard coupling conditions, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIEA). Amide-type harmicines exerted remarkable activity against the erythrocytic stage of P. falciparum, in low submicromolar concentrations, which was significantly more pronounced compared to their antiplasmodial activity against the hepatic stages of P. berghei. Furthermore, a cytotoxicity assay against the human liver hepatocellular carcinoma cell line (HepG2) revealed favorable selectivity indices of the most active harmicines. Molecular dynamics simulations demonstrated the binding of ligands within the ATP binding site of PfHsp90, while the calculated binding free energies confirmed higher activity of N-harmicines 5 over their O-substituted analogues 6. Amino acids predominantly affecting the binding were identified, which provided guidelines for the further derivatization of the harmine framework towards more efficient agents.
Open AccessNovel Harmicines with Improved Potency against Plasmodium
Harmicines represent hybrid compounds composed of β-carboline alkaloid harmine and cinnamic acid derivatives (CADs). In this paper we report the synthesis of amide-type harmicines and the evaluation of their biological activity. N-harmicines 5a–f and O-harmicines 6a–h were prepared by a straightforward synthetic procedure, from harmine-based amines and CADs using standard coupling conditions, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIEA). Amide-type harmicines exerted remarkable activity against the erythrocytic stage of P. falciparum, in low submicromolar concentrations, which was significantly more pronounced compared to their antiplasmodial activity against the hepatic stages of P. berghei. Furthermore, a cytotoxicity assay against the human liver hepatocellular carcinoma cell line (HepG2) revealed favorable selectivity indices of the most active harmicines. Molecular dynamics simulations demonstrated the binding of ligands within the ATP binding site of PfHsp90, while the calculated binding free energies confirmed higher activity of N-harmicines 5 over their O-substituted analogues 6. Amino acids predominantly affecting the binding were identified, which provided guidelines for the further derivatization of the harmine framework towards more efficient agents.
- 1 August 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (16) , 127336
Chloroquine fumardiamides as novel quorum sensing inhibitors
- 1 August 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (16) , 127336
Chloroquine fumardiamides as novel quorum sensing inhibitors
- 1 February 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 187, 111927
Harmicines − harmine and cinnamic acid hybrids as novel antiplasmodial hits
- 1 February 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 187, 111927
Harmicines − harmine and cinnamic acid hybrids as novel antiplasmodial hits
- 1 November 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 182, 111640
Primaquine derivatives: Modifications of the terminal amino group
- 1 November 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 182, 111640
Primaquine derivatives: Modifications of the terminal amino group
- Open Access
- 21 October 2019
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 69 (4) , 661-672
Antiproliferative evaluation of various aminoquinoline derivatives
Four classes of aminoquinoline derivatives were prepared: primaquine ureas 1a – f , primaquine bis-ureas 2a – f , chloroquine fumardiamides 3a – f and mefloquine fumardiamides 4a – f . Their antiproliferative activities against breast adeno-carcinoma (MCF-7), lung carcinoma (H460) and colon carcinoma (HCT 116 and SW620) cell lines were evaluated in vitro , using MTT cell proliferation assay. The results revealed a low activity of primaquine urea and bis-urea derivatives and high activity of all fumardiamides, with IC 50 values in low micromolar range against all tested cancer cell lines.
- 21 October 2019
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 69 (4) , 661-672
Open AccessAntiproliferative evaluation of various aminoquinoline derivatives
Four classes of aminoquinoline derivatives were prepared: primaquine ureas 1a – f , primaquine bis-ureas 2a – f , chloroquine fumardiamides 3a – f and mefloquine fumardiamides 4a – f . Their antiproliferative activities against breast adeno-carcinoma (MCF-7), lung carcinoma (H460) and colon carcinoma (HCT 116 and SW620) cell lines were evaluated in vitro , using MTT cell proliferation assay. The results revealed a low activity of primaquine urea and bis-urea derivatives and high activity of all fumardiamides, with IC 50 values in low micromolar range against all tested cancer cell lines.
- 1 October 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (19) , 126614
Primaquine homodimers as potential antiplasmodial and anticancer agents
- 1 October 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (19) , 126614
Primaquine homodimers as potential antiplasmodial and anticancer agents
- Open Access
Primaquine and Chloroquine Fumardiamides as Promising Antiplasmodial Agents
This paper describes a continuation of our efforts in the pursuit of novel antiplasmodial agents with optimized properties. Following our previous discovery of biologically potent asymmetric primaquine (PQ) and halogenaniline fumardiamides (1–6), we now report their significant in vitro activity against the hepatic stages of Plasmodium parasites. Furthermore, we successfully prepared chloroquine (CQ) analogue derivatives (11–16) and evaluated their activity against both the hepatic and erythrocytic stages of Plasmodium. Our results have shown that PQ fumardiamides (1–6) exert both higher activity against P. berghei hepatic stages and lower toxicity against human hepatoma cells than the parent drug and CQ derivatives (11–16). The favourable cytotoxicity profile of the most active compounds, 5 and 6, was corroborated by assays performed on human cells (human breast adenocarcinoma (MCF-7) and non-tumour embryonic kidney cells (HEK293T)), even when glucose-6-phosphate dehydrogenase (G6PD) was inhibited. The activity of CQ fumardiamides on P. falciparum erythrocytic stages was higher than that of PQ derivatives, comparable to CQ against CQ-resistant strain PfDd2, but lower than CQ when tested on the CQ-sensitive strain Pf3D7. In addition, both sets of compounds showed favourable drug-like properties. Hence, quinoline fumardiamides could serve as a starting point towards the development of safer and more effective antiplasmodial agents.
Open AccessPrimaquine and Chloroquine Fumardiamides as Promising Antiplasmodial Agents
This paper describes a continuation of our efforts in the pursuit of novel antiplasmodial agents with optimized properties. Following our previous discovery of biologically potent asymmetric primaquine (PQ) and halogenaniline fumardiamides (1–6), we now report their significant in vitro activity against the hepatic stages of Plasmodium parasites. Furthermore, we successfully prepared chloroquine (CQ) analogue derivatives (11–16) and evaluated their activity against both the hepatic and erythrocytic stages of Plasmodium. Our results have shown that PQ fumardiamides (1–6) exert both higher activity against P. berghei hepatic stages and lower toxicity against human hepatoma cells than the parent drug and CQ derivatives (11–16). The favourable cytotoxicity profile of the most active compounds, 5 and 6, was corroborated by assays performed on human cells (human breast adenocarcinoma (MCF-7) and non-tumour embryonic kidney cells (HEK293T)), even when glucose-6-phosphate dehydrogenase (G6PD) was inhibited. The activity of CQ fumardiamides on P. falciparum erythrocytic stages was higher than that of PQ derivatives, comparable to CQ against CQ-resistant strain PfDd2, but lower than CQ when tested on the CQ-sensitive strain Pf3D7. In addition, both sets of compounds showed favourable drug-like properties. Hence, quinoline fumardiamides could serve as a starting point towards the development of safer and more effective antiplasmodial agents.
- Open Access
- 28 March 2019
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 69 (2) , 233-248
Synthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides
The paper is focused on the synthesis and screening of the antiplasmodial activity of novel fumardiamides 5–10 with the mefloquine pharmacophore and a Michael acceptor motif. Multi-step reactions leading to the title compounds included two amide bond formations. The first amide bond was achieved by the reaction of ( E )-ethyl 4-chloro-4-oxobut-2-enoate ( 1 ) and N 1 -(2,8-bis(trifluoromethyl)quinolin-4-yl) butane-1,4-diamine ( 2 ). The obtained ester 3 was hydrolyzed and gave acid 4 , which then reacted with the selected halogenanilines in the presence of HATU/DIEA and formed products 5–10 . Title compounds showed marked, dose dependent activity in vitro against hepatic stages of Plasmodium berghei. IC 50 values of the most active compounds 5 , 7 and 9 bearing 3-fluoro, 3-chloro and 3-trifluoromethyl substituents were 3.04–4.16 µmol L −1 , respectively. On the other hand, the compounds exerted only weak activity against the erythrocytic stages of two P. falciparum strains ( Pf 3D7 and Pf Dd2) in vitro , with the exception of compound 5 ( IC 50 = 2.9 µmol L −1 ).
- 28 March 2019
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 69 (2) , 233-248
Open AccessSynthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides
The paper is focused on the synthesis and screening of the antiplasmodial activity of novel fumardiamides 5–10 with the mefloquine pharmacophore and a Michael acceptor motif. Multi-step reactions leading to the title compounds included two amide bond formations. The first amide bond was achieved by the reaction of ( E )-ethyl 4-chloro-4-oxobut-2-enoate ( 1 ) and N 1 -(2,8-bis(trifluoromethyl)quinolin-4-yl) butane-1,4-diamine ( 2 ). The obtained ester 3 was hydrolyzed and gave acid 4 , which then reacted with the selected halogenanilines in the presence of HATU/DIEA and formed products 5–10 . Title compounds showed marked, dose dependent activity in vitro against hepatic stages of Plasmodium berghei. IC 50 values of the most active compounds 5 , 7 and 9 bearing 3-fluoro, 3-chloro and 3-trifluoromethyl substituents were 3.04–4.16 µmol L −1 , respectively. On the other hand, the compounds exerted only weak activity against the erythrocytic stages of two P. falciparum strains ( Pf 3D7 and Pf Dd2) in vitro , with the exception of compound 5 ( IC 50 = 2.9 µmol L −1 ).